UCB SA (UCBJY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

United Commercial Bank PLC (UCB) has signed a Memorandum of Understanding (MoU) with the National Pension Authority (NPA), ...

The pharma began its outreach to the HS community well before securing Bimzelx’s approval in the indication. In the spring of ...

UCB, a global biopharmaceutical company, today announced the expansion of its "Get Yourself Back" direct-to-consumer (DTC) advertising campaign for BIMZELX® (bimekizumab-bkzx). This campaign aims to ...

A UC Berkeley marketing professor was reportedly shot and killed by a masked attacker in Greece earlier this month. According to a report in the UCB student newspaper, the Daily Californian, ...

UCB is flawed, but it’s important, and it can change the world, or at least the entertainment industry. That won’t happen unless it pays the people who give it a reason to exist.

Belgian drugmaker UCB has agreed to pay $1.9 billion to acquire Zogenix, a company whose flagship drug is commercialized for one particular rare type of epilepsy and holds potential as a treatment ...

A UCB drug with a novel approach to plaque psoriasis won a long-awaited FDA approval, positioning it to bring patients a new choice in a crowded market of products for the prevalent skin condition.

UCB benefits from its geographic diversity, as the company sells drugs in the U.S. (representing 62% of 2022 sales), Europe (26% of 2022 sales), and Japan (13% of 2022 sales).

UCB UCB remains focused on expanding its addressable patient population and developing its pipeline as the company continues to face generic competition. UCB received positive opinions from the ...

Mark Bodmer and Jonathan Lewis of UCB pharma talk us though the partnering model at UCB, and how partnering can drive innovation. The world is changing and it’s no different for the ...

Upright Citizens Brigade, the improv mainstay and launchpad for many comics, will no longer have a physical space in New York City. Despite UCB's flaws, "people are grieving," a former UCBer says.